Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TENACITY – Tenecteplase vs standard of care in late-window acute ischemic stroke
2025-522542-40-00Phase 3Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial in ischemic stroke comparing Tenecteplase arm with Standard of care arm (2 arms). Primary endpoint: mRS 0-1 at Day 90. Planned start Mar 2026; status: authorised.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2025-522542-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522542-40-00.